| 47.37 -1.85 (-3.76%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 60.83 | 1-year : | 64.94 |
| Resists | First : | 52.08 | Second : | 55.59 |
| Pivot price | 51.66 |
|||
| Supports | First : | 46.4 | Second : | 38.6 |
| MAs | MA(5) : | 48.97 |
MA(20) : | 51.46 |
| MA(100) : | 46.76 |
MA(250) : | 48.59  |
|
| MACD | MACD : | -0.3 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 15.3 |
D(3) : | 20.5 |
| RSI | RSI(14): 38.9 |
|||
| 52-week | High : | 94.9 | Low : | 18.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GPCR ] has closed above bottom band by 5.9%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.25 - 49.66 | 49.66 - 49.92 |
| Low: | 46.18 - 46.61 | 46.61 - 46.9 |
| Close: | 46.8 - 47.47 | 47.47 - 47.92 |
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Mon, 24 Aug 2026
Structure Therapeutics (GPCR): Can Upcoming Obesity Trial Catalysts Help Regain Its Form? - RTTNews
Fri, 21 Aug 2026
GPCR News | STRUCTURE THERAPEUTICS INC (NASDAQ:GPCR) - ChartMill
Fri, 21 Aug 2026
Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR) - Seeking Alpha
Wed, 19 Aug 2026
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
Sat, 08 Aug 2026
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Sat, 08 Aug 2026
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Stifel Nicolaus - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 97.6 (%) |
| Shares Short | 6,050 (K) |
| Shares Short P.Month | 6,130 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -220 (M) |
| Levered Free Cash Flow | -119 (M) |
| PE Ratio | -15.64 |
| PEG Ratio | 0 |
| Price to Book value | 2.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|